HOME >> MEDICINE >> NEWS
AstraZeneca announces SYMBICORT is now available in the US

Wilmington, Del. June 25, 2007 -- AstraZeneca announced today that SYMBICORT (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler (pMDI) is now available in the United States for the long-term maintenance treatment of asthma in patients 12 years of age and older.

Administered twice daily, SYMBICORT is a combination of two proven asthma medications budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). For many patients, this combination treatment offers improved asthma control as early as day one that is sustained over 12 weeks. SYMBICORT also delivers improved lung function occurring within 15 minutes of beginning treatment. SYMBICORT does not replace fast-acting inhalers for sudden attacks.

SYMBICORT is available in two dose strengths, 80/4.5 and 160/4.5 mcg of budesonide and formoterol, respectively. SYMBICORT is approved for patients whose disease is not adequately controlled on another asthma-controller medication (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies.

With the U.S. launch of SYMBICORT, millions of asthma sufferers will have a new choice of fixed combination therapy to help achieve control of their asthma, said Chris OBrien, MD, PhD, senior director, Medical Science, AstraZeneca.

Asthma is one of the most serious chronic diseases in the U.S. It is estimated that more than 20 million Americans suffer from the condition and, if not properly managed, asthma can be life-threatening.

The U.S. availability of SYMBICORT holds great promise for millions of Americans that suffer from asthma, said Tony Zook, president and chief executive officer, AstraZeneca U.S. The addition of SYMBICORT to our respiratory portfolio reinforces AstraZenecas commitment to developing new, effective treatments, and provides patients and physicians
'"/>

Contact: Tracy Knudsen
Tracy.Knudsen@astrazeneca.com
302-885-1933
AstraZeneca
25-Jun-2007


Page: 1 2

Related medicine news :

1. AstraZeneca, University of Miami, and Humana collaborate to improve consumer health
2. AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration agreements
3. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
4. Weill Cornell Medical College announces gifts totaling $400M
5. GSK announces launch of largest ever Phase III trial in lung cancer treatment
6. Elsevier announces launch of Brain Stimulation
7. NSW Premier announces $15M for childrens cancer research
8. National Inventors Hall of Fame announces 2007 inductees
9. Emory University announces new Global Health Institute
10. BioMed Central announces Journal of Medical Case Reports
11. Tibotec Therapeutics announces start of largest US study on HIV treatment in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... ... May 24, 2016 , ... United ... to welcome new Partner Firm Austin & Co., Inc. Headquartered in Albany, ... employee benefits, HR consulting, benefits technology, and beyond. As an employee-owned company ...
(Date:5/24/2016)... ... May 24, 2016 , ... Educational ... to housing, with more advantaged communities providing richer opportunities. Recognizing the key role ... (a) school improvement policies; (b) school choice policies; (c) school desegregation policies; (d) ...
(Date:5/24/2016)... ... ... How to Write Error Free Procedures, **Presented by Ginette M. Collazo and ... known to be the major cause of quality and production losses in many industries. ... performance problems can be prevented. , How to Write Error Free Procedures, part two ...
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog Citizens ... of Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its protest against ... Industry of Death” exhibit in Atlanta, Georgia. The opening of the exhibit follows CCHR’s ...
(Date:5/24/2016)... , ... (PRWEB) May ... three new members of its Advisory Board. Joining the Grow ... Kusch. “All three of them embody the mission of our organization ... very fortunate to have them as we continue to expand our ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... -- Clarifying Vision - Prospects and Developments ... Care What can be expected from the ... at the fastest rates? This visiongain report ... opportunities and prospects. ,Our 190-page report ... lucrative areas in the industry and the future market ...
(Date:5/23/2016)... Non-invasive diagnostic test realizes the potential of ... be presented at Yissum’s booth, at IATI-BIOMED 2016 conference  ... the Hebrew University of Jerusalem announced today it ... MKI, the technology investment arm of Morris Kahn , ... early detection of multiple diseases by analyzing circulating DNA ...
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
Breaking Medicine Technology:
Cached News: